Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.S. Suspends J&J Covid-19 Vaccine Shipments as States Face a Surplus of Expiring Doses -- 4th Update

06/10/2021 | 05:08pm EDT

By Jared S. Hopkins and Betsy McKay

The U.S. government has halted new shipments of the Johnson & Johnson Covid-19 vaccine, according to state and federal health officials, one of several steps federal agencies are taking that could help clear a backlog of unused doses before they expire.

The U.S. Centers for Disease Control and Prevention has stopped making available the one-dose shot to states, the state and federal health officials said. The stoppage is believed to be temporary, some of these officials said.

Health officials from Maryland, Oklahoma, Arkansas, Michigan, Illinois and other states said they haven't been able to order new supplies of J&J doses in recent weeks. Some also said they have sufficient supply of the vaccine.

"It just hasn't been included in our weekly allocations, from the feds, which means it is not available to order," said Oklahoma State Department of Health Deputy Commissioner Keith Reed.

The move comes as the U.S. Food and Drug Administration separately extended the shelf life of J&J's vaccine to 4 1/2 months from three months once refrigerated, the drugmaker said Thursday.

It couldn't be determined why the federal government suspended the shipments, but the policy change comes as both federal and state health officials are trying to use up J&J doses that have sat on shelves so long they are set to expire.

Public-health experts say the suspension of shipments and the vaccine's shelf-life extension should prevent a further buildup in J&J doses and allow the existing stockpiles to be drawn down, although officials still have to contend with the slowing pace of vaccinations in the U.S.

The new expiration date "helps with the immediate issue of them not ending up in the trash can," said Amesh Adalja, senior scholar at the Johns Hopkins Center for Health Security. He said it is crucial for states and the federal government to keep working to expand access and bring the vaccine to areas that need it. "They really just have to pull out all the stops and not waste the vaccine."

Asked to comment on the government's decision to limit availability of the vaccine to states, a J&J spokesman said, "We continue to work with the U.S. government and health authorities to support the use of our vaccine, which continues to play an important role, including among those who wish to be fully vaccinated with one shot."

Just over half of the approximately 21 million J&J doses distributed in the U.S. have been administered, a lower percentage compared with shots from Pfizer Inc. and Moderna Inc., according to the CDC. J&J has committed to deliver 100 million doses by the end of June, although it has been delayed by manufacturing problems.

Hospital and state officials said they have many J&J doses expiring later this month, partly as an unintended consequence of the U.S.'s decision in April to temporarily suspend administration of J&J doses to assess a rare blood-clot risk.

The pause forced states and providers to cancel large blocks of appointments that were never rescheduled and left a surplus of supply and, in some areas, increased hesitancy over the J&J vaccine's safety.

The J&J vaccine was authorized by the U.S. Food and Drug Administration in February after researchers found it to be effective in a large-scale trial at protecting against symptomatic Covid-19.

While its efficacy was slightly lower than Pfizer and Moderna shots, public-health officials and vaccine experts had high hopes for the shot's role in the vaccine drive -- because it was a single-shot and required fewer cold-chain restrictions.

J&J stores doses frozen until shipment by the government, at which point they are refrigerated. That is when the countdown starts for expiration.

State health officials said they haven't been able to order new doses of the J&J shot since mid-May. The CDC has been restricting orders of the J&J vaccine, the federal health official said.

A spokeswoman for the Arkansas state health department said it was informed that no doses were available for ordering because of issues related to the manufacturing of the vaccine.

Maryland last ordered J&J doses several weeks ago and has since been told by the government that the vaccine isn't available, Maryland Department of Health Assistant Secretary Bryan Mroz said in an interview. Federal officials say J&J's shot will become available again but didn't say when that would be, he said.

"We've been using up our inventory in the state," Mr. Mroz. "We definitely have more supply than demand."

Mr. Mroz said that some doses will expire at the end of June and others in July and that the state is working to redistribute some to providers who request them.

A Maryland spokesman said Thursday the state would follow the new FDA guidelines extending the vaccine's shelf life. "We are focused on getting as many of the approximately 74,000 J&J doses into as many arms as possible before they expire per the new FDA shelf-life guidelines," he said.

The extended expiration date is likely to help states and providers that have been seeking guidance from the federal government on what to do with the expiring doses.

Thomas M. Burton and Julie Wernau contributed to this article.

Write to Jared S. Hopkins at jared.hopkins@wsj.com and Betsy McKay at betsy.mckay+1@wsj.com

(END) Dow Jones Newswires

06-10-21 1908ET

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL 0.95% 34196.82 Delayed Quote.10.68%
MODERNA, INC. 3.82% 220.14 Delayed Quote.110.72%
PFIZER, INC. 0.36% 39.19 Delayed Quote.6.47%
All news about MODERNA, INC.
04:06aPFIZER  : Fact Check - Is There Lack of Storage Facilities for Covid-19 Vaccines..
AQ
06/24MODERNA  : U.S. administers 320.7 mln doses of COVID-19 vaccines - CDC
RE
06/24MODERNA  : U.S. CDC Says Administered 320,687,205 Doses Of Covid-19 Vaccine As O..
RE
06/24MODERNA  : U.S. CDC Says Delivered 379,248,700 Doses Of Covid-19 Vaccine As Of J..
RE
06/24ASTRAZENECA  : Swiss health ministry data shows vaccinated people seldom hit by ..
RE
06/24ASTRAZENECA  : EU slightly cuts estimates for vaccine deliveries this year
RE
06/24WHO estimates COVID-19 boosters needed yearly for most vulnerable
RE
06/24MODERNA  : Argus Adjusts Moderna's Price Target to $230 From $200, Reiterates Bu..
MT
06/24DOW JONES FXCM DOLLAR INDEX  : NAB on Updated Australia's COVID-19 Vaccine Suppl..
MT
06/24MODERNA  : Hopes To Speed Up Delivery Of COVID-19 Vaccine To Germany
MT
More news
Financials (USD)
Sales 2021 18 632 M - -
Net income 2021 10 719 M - -
Net cash 2021 11 520 M - -
P/E ratio 2021 8,92x
Yield 2021 -
Capitalization 88 392 M 88 392 M -
EV / Sales 2021 4,13x
EV / Sales 2022 4,25x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 220,14 $
Average target price 168,87 $
Spread / Average Target -23,3%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.110.72%88 392
LONZA GROUP AG16.70%53 670
IQVIA HOLDINGS INC.34.45%46 441
CELLTRION, INC.-22.42%33 607
SEAGEN INC.-10.13%28 564
PHARMARON BEIJING CO., LTD.73.47%24 838